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Abstract  
Evidence for the need for high data quality in clinical research is well established. The rigor of clinical research conclusions 
rely heavily on good quality data, which relies on good documentation practices. Little attention has been given to clear 
guidelines and definitions to monitor data quality. To address this, a “fit-for-use” data quality monitoring framework 
(DQMF) for clinical research was developed based on a holistic design-oriented approach. An integrated literature review 
and feasibility study underpinned the framework development. Ontology of key terms, concepts, methods, and standards 
were recorded using a consensus approach and mind mapping technique. The DQMF is presented as a nested concentric 
network illustrating concept relationships and hierarchy.  Face validation was conducted, and common terminology and 
definitions are listed.  The consolidated DQMF can be adapted according to study context and data availability aiding in the 
development of a long-term strategy with increased efficacy for clinical data quality monitoring.  
Introduction  
Regardless of study design or clinical area, high quality data collection and standardized data processing and representation 
are paramount to ensure reliable research findings1-3. Evidence has linked poor data quality to incorrect conclusions and 
recommendations4-7. Preventing data error is key during the development, design, and collection of clinical data8. The 
National Institute of Health (NIH)9 broadly defines a clinical trial as “a research study in which one or more human subjects 
are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects 
of those interventions on health-related biomedical or behavioral outcomes” [para. 3]. With this broad definition, several 
challenges arise to ensure high data quality due to different clinical objectives and requirements for data. Many strategies and 
interventions have been developed and are aimed at reducing error in clinical trials, including standard operating procedures 
(SOPs), personnel training, data monitoring or auditing and careful design of case report forms (CRF). However, current 
international and national guidelines lack consistency, creating uncertainty for clinical researchers. Therefore, in order to 
optimize data quality, standard procedures must be implemented.  
The need for high data quality in clinical research has been well established. The term ‘data quality’, sometimes referred to as 
information quality10, is a multidimensional and hierarchical concept11. The World Health Organization (WHO)12 defines 
data quality as “ …the ability to achieve desirable objectives using legitimate means. Quality data represents what was 
intended or defined by their official source, are objective, unbiased and comply with known standards” [pg.10]. An alternate 
definition emerged from Kerr et al.13 who suggested that good data quality is data “fit for use” [pg.5] for the objectives of 
data collection. High data quality is crucial to a research organization’s success, while poor data quality (often referred to as 
‘dirty data’) can significantly impact on the productivity of a business or institution14. It is essential to minimize errors, as a 
poorly designed study with inferior data points and results cannot be redeemed. In the context of clinical research, data that is 
not “fit for use” may lead to biased results, conclusions, and recommendations and may compromise participant health. To 
date, there is a lack of a precise definition for data quality. This, in turn, creates misunderstandings that may weaken the 
validity and reliability of data quality assessment and monitoring methods4.  
Data management needs to be consistent, effective and efficient within each study8, 15. Regardless of the method used to 
collect, handle and store the data collected within clinical trials, a vigorous management system is essential. For academic 
clinical trials, developing and maintaining a data management system is a challenge16. This is largely due to special 
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requirements for individual trials, for example, the need to implement specific frameworks, and the expense to develop and 
run the software which also requires a sophisticated information technology infrastructure17.  Academic clinical trials are less 
likely to implement common clinical data management systems such as those utilized within the pharmaceutical industry 
(e.g. Oracle Clinical); instead they often implement specialized, in-house smaller systems18. A recent survey found that 
considerable heterogeneity in data management exists and limited open access or freely available standard documents are 
available18. Furthermore, over 50% of the surveyed clinical research centers stated that although they had a data management 
system in place, the system did not comply with guidelines and legal requirements (GCP, ECRIN, FDA, GAMP, and ISO) 
for both internal system and independent validation by an external auditor. Similarly, survey results from the Association of 
Academic Health Centers (AAHC) highlighted that the greatest barrier for clinical trial operations was a lack of resources, 
systems, and procedures within the organisation19. It is clear that clinical trials, especially within the academic research 
community, need a standardized, open-source data monitoring framework to improve the quality level and best practice.  
With rapid developments in technology, clinical research now relies heavily on the evaluation of automatic and electronically 
communicated data for critical decision-making through which data quality has become increasingly important. Emerging 
literature on technological improvements, demonstrate new opportunities and concerns about the reuse of clinical research 
data. The American Medical Informatics Association have compiled recommendations and also stressed the urgency and 
complexity of issues that surround the secondary use of clinical data20. Additionally, the primary obstacle to integrated data 
repositories was data quality21. In an effort to overcome this issue and to continuously improve data quality; standard 
monitoring methods are required before, during and after primary data collection, and at a larger-scale for the reuse of clinical 
data in research. To optimize quality, clinical studies should implement and publish their approach to monitor data quality to 
increase efficacy, reduce costs and follow procedures designed to minimize inaccurate and incomplete data. 
The aim of this research was to develop a “fit-for-use” data quality monitoring framework (DQMF) for clinical research. This 
framework will aid clinical trials in obtaining and maintain high data quality by providing guidance on critical areas that 
relate to trial operations throughout the clinical research process.  
Framework development  
When determining data quality criteria there are different approaches that can be applied, which include empirical, 
practitioner-based, theoretical, literature-based, pragmatic and design-oriented22, 23. For the purpose of this research, a holistic 
design-oriented approach was applied to design and develop the DQMF. A design-oriented approach provided guidance to 
the researchers to create the framework (artefact) and further understand the apparent reality of different stakeholders 
(clinical research trials) of the framework24. This provided further guidance to the researchers by helping to recognize data 
failures by developing the framework against a real-world state25. Design science is considered a problem-solving paradigm 
and seeks to extend the boundaries of the human and organizational capabilities by creating new and innovative artefacts26. 
The purpose of such artefacts is to improve the efficiency and effectiveness of the organization’s characteristics, the work 
systems and its employee’s capabilities. Design science argues that human knowledge and understanding of the problem and 
the solution are acquired in the ‘building’ and the ‘application’ of the artefact. Therefore, this research follows the conceptual 
framework and seven guidelines proposed by Hevner et al.26 for understanding, executing and evaluating design-oriented 
research. This creative design process utilised a build-and-evaluate loop iteration to the evolving design of the generated 
artefact. This preliminary methodological research focuses largely on the ‘build’ process of the resulting artefact, keeping in 
mind that further evaluation and testing needs to be conducted. Overall, the proposed framework aims to help those 
designing, implementing and working in clinical research to understand the complex inter- and intra-relationships between 
the concepts that need to be planned both methodically and structurally, in order to improve the data quality of clinical 
research. 
The initial design of the DQMF was guided by an integrated literature review and feasibility study27 of data quality concepts, 
from an information sciences and clinical grounding. Outcomes from the feasibility study determined that clinical trials are 
implementing ad hoc methods pragmatically to ensure data quality. Thus, there is a necessity for further research into 
‘standard practice’. The ontology of key terms, concepts, methods, and standards were extracted and recorded from the 
literature review and feasibility study survey questions. Consensus approach and mind mapping techniques were used to 
present associations in a non-linear diagram/network28. The dependent variable, ‘data quality monitoring’ was placed at the 
centre of the network to compose the mind map where associations were added and ‘branched’. This process was undertaken 
by the researchers (L.H., P.Y., A.M. and Y.P.) to foster a natural thinking process, allowing for the addition of new concepts, 
1301
relationships and annotations29. Furthermore, branches and nodes were grouped together under comparable topic areas via 
researcher agreement to construct a hierarchical tree-like figure.  
Once the researchers (L.H., P.Y., A.M. and Y.P.) came to a consensus, the DQMF was presented to a convenient sample 
(n=8) of working health professionals (dieticians, nutritionists, educators, public health practitioners) for face validity testing. 
Participants had clinical research experience (1 – 15+ years) in university academic, private institute and hospital settings. 
The primary researcher (L.H) moderated the interactive one-hour workshop, which aimed to gain feedback on the design and 
useability of the proposed DQMF within different clinical research settings. Each participant was provided an individual copy 
of the DQMF and encouraged to make note of any questions or issues. The workshop communicated the process by which 
the artefact was created and defined as the mechanism to finding an effective and efficient solution. Once the background 
information was presented, participants were asked to refine and make relevant changes to the DQMF based on their own 
knowledge and expertise. The primary researcher (L.H) then opened up the discussion to the group to explore reasons why 
amendments were suggested to fit each of the participant’s clinical focus. The workshop identified that standardized 
terminologies, definitions and dialogue are crucial to the success of the DQMF. According to participants’ responses, 
amendments to the DQMF were discussed and agreed upon and a supporting list of key terms and definitions were devised. 
Each stage of the systematic framework development was aligned with the international guidelines (GCP, ECRIN, FDA, 
GAMP, and ISO) to ensure the taxonomy and terminology used complied with global standard procedures and policies.  
Data Quality Monitoring Framework (DQMF)  
Refinement and evaluation of the key concepts has led to the development of the DQMF. This framework contains the key 
components of data quality, data quality monitoring, and data quality management presented in a nested concentric network 
to illustrate the relationships and hierarchy (Figure 1). Each layer of the framework contains specific and highly important 
procedures and concepts undertaken within each layer. The importance of training and education is highlighted by its 
expansion across all layers of the DQMF. It was determined in the stakeholder workshop that dialogue, definitions, and 
terminology should be implemented consistently across clinical research. Due to the need to clarify terminology related to the 
DQMF and ensure effective communication we have included Table 1, which highlights key terms and their definitions 
related specifically to the DQMF. 
 
Figure 1: The data quality monitoring framework  
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Four key independent variables were identified (inner layer) and adapted from Nahm30 who illustrates the way data 
definition, collection, processing and representation are each handled, impacts data use which impacts on data and 
information quality. On the contrary, data and information quality in turn impact use. The data evolution life cycle (DELC) 
was deliberated for inclusion within the inner tier throughout the development of the DQMF as it reflects a sequence of 
stages known as data collection, organization, presentation, and application31. The researchers chose not to integrate this 
cycle as they believe the stages of collection, organization and presentation relate closely to the terminology and stages of 
Nahm’s30 framework of collection, processing and representation, respectively. Additionally, the DQMF main focus is ‘data 
quality monitoring’ in which Nahm’s framework was designed to highlight the factors that affect data quality while the 
DELC represents data evolution.  The addition of ‘application’ was discussed, however, the researchers believe that the 
framework illustrates how data is utilized and applied in clinical research by linking ‘data’ to ‘information’.  
Data quality monitoring was separated into two main concepts; quality assurance and quality control (middle tiers). The 
terms quality assurance and quality control are often used inaccurately or interchangeably8. Quality assurance is the process 
to “prevent” data errors, which includes the methods such as audits and other methods/techniques to ensure data integrity. 
Auditing is a recognized method that has been used to assess and develop the quality of information32, 33. Quality assurance 
audits within clinical and healthcare settings are extensively employed and are the major strategy to ensure high-quality 
data30, 34-36.  Quality assurance activities include examining the design of case report forms, analyzing the data collection 
techniques and regular training of data entry personnel and data management37, 38. On the other hand, quality control is the 
process to “alleviate” or “remove” the impact of errors that have occurred during data collection and/or analysis15. This refers 
to the operational techniques used to fulfil requirements for quality. Recognised methods of quality control include the 
conduct of periodic monitoring (daily, weekly, and monthly) through pragmatic data range and consistency checks, query 
management, and double data entry to minimize errors8. Therefore, quality control is the continuous quality assurance 
activity undertaken to verify clinical trial-related processes to fulfil the agreed standards.  
Data quality management and data governance (the outer tiers) include developing and implementing national and internal 
standards and regulations in the full data life cycle, including planning before and execution of protocols and policies for data 
capture and analysis. Currently,there is no open access Good Clinical Practice (GCP) standard on data monitoring that is 
broadly recognized, detailed and applicable to all clinical research. Therefore, the design of the DQMF has drawn upon an 
illustration by Ohmann et al.16 who highlight the central importance of the International Conference on Harmonisation (ICH)-
GCP guidelines within clinical research at an international level and within the United States of America regulations and the 
European Union directives. The illustration links regulations and guidelines that are relevant to GCP-compliant computer 
systems and data management practices connecting important references from one document to another. The researchers took 
guidance from Ohmann’s work and extracted key concepts within each of the regulatory requirements and documents. In 
light, the researchers agreed a simpler and broader approach was required to guide clinical researchers by providing 
overarching concepts of infrastructure, protocol and regulations/standards. This approach will allow clinical researchers to 
make an informed decision regarding the most suitable management strategy to their individual trial while incorporating and 
highlighting legal requirements. Further, it will acknowledge the broad range of clinical research trials and the fact that 
healthcare requires person-to-person interactions for collaboration and integration between strategy, process (automated/non-
automated) and the supporting information systems. As the feasibility study that guided this research found heterogeneity in 
data management practices with only 50% of respondents reporting to have a data management plan in place27. By providing 
a consolidated framework to optimize the efficacy of data management, the researchers aim to provide clear guidance to 
clinical research data quality monitoring that is both time and cost effective.  




Audit A systematic and independent examination of trial-related activities and documents to 
determine whether these activities were conducted, and the data were recorded, analyzed and 
accurately reported according to the protocol, the sponsor, SOP, GCP and applicable 
regulatory requirements39.  





Systematically planning, collecting and assessing data to distinguish a chance to ameliorate 
the process of clinical trial data management40, 41.   
CRF/eCRF Case report form/electronic case report form: A printed, optical or electronic document 
designed to record all of the protocol-required information39.  
Data An individual fact or pieces of information.  
Data collection The process by which data elements are accumulated3. 
Data definition Occurs as the protocol or research plan is developed. Procedures include identifying data to be 
collected, defining data elements and designing CRFs3.  
Data governance Encompasses people, processes and information technology required to formally manage and 
exercise control over methods used by data stewards and data custodians in order to improve 
data quality42.  
Data processing The processes and systems applied to audit and monitor data3. 
Data representation Relates to data analysis and the process of translating data into meaningful information3. 




The development, execution, and supervision of plans, policies, programs and practices that 
control, protect, deliver and enhance the value of data and information assets44.  
Data quality 
monitoring 
The oversight and review of research processes, procedures, records, data reporting, 
appropriate conduct and ongoing evaluation.  
Education and training  The knowledge or skills obtained or developed by a learning process and the further 
instruction and education to an agreed standard of proficiency.  
Information A collection of data or facts. 
Infrastructure Buildings, supplies, policies, procedures, information technology and other assets that support 
the human resources of an organization.  
Methods and 
techniques  
Risk-based monitoring: A mixed method approach focused on the critical data points and 
processes that are identified to have the most risk via a targeted or triggered assessment27.  
Remote monitoring: Data monitored off-site, includes delivering documents via email, fax or 
snail mail to monitoring personnel to conduct source data verification27. 
Centralised monitoring: Data collected through an electronic data capture and queries 
identified by a monitor that may need further attention to alleviate problems27. 
Source data verification: Comparing source data (original or certified copy) documents to 
data recorded or entered into a case report form or electronic record or database27. 
On-site monitoring: All monitoring activities undertaken at the clinical trial site45. 
Manual of operations 
(MOP) 
A handbook of instructions designed to guide the research team to successfully carry out 
aspects of a research project according to the research protocol46.  
Monitoring The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, 
recorded, and reported in accordance with the protocol, SOPs, GCP and the applicable 
regulatory requirement(s)39. 
Policy  Communicates and documents an organizations overall intentions and direction with respect 
to quality. A written quality policy, and top-level management should demonstrate 
commitment to the quality policy by supporting the organization's infrastructure with adequate 
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resources. Off-line quality control activities, such as quality engineering, quality planning, and 
procedures applicable to each study, will be enhanced by this infrastructure and facilitate error 
prevention42.  
Protocol A document that describes the objective(s), design, methodology, statistical considerations 
and organization of a trial. The protocol usually gives the background and rationale for the 
trial, but these could be provided in other protocol referenced documents39. 
Quality assurance  All those planned and systematic actions that are established to ensure that the trial is 
performed, and the data are generated, documented (recorded), and reported I compliance with 
GCP and applicable regulatory requirements39. 
Quality control The operational techniques and activities undertaken within the quality assurance system to 
verify that the requirements for quality of the trial-related activities have been fulfilled39. 
Regulations/ 
standards  
International Organisations for Standardisation (ISO)47: ISO 14155:2011 – Clinical 
investigation of medical devices for human subjects – Good Clinical Practice: This 
International Standard specifies general requirements intended to; protect the rights, safety 
and well-being of human subjects, ensure the scientific conduct of the clinical investigation 
and the credibility of the clinical investigation results, define the responsibilities of the 
sponsor and principal investigator, and assist sponsors, investigators, ethics committees, 
regulatory authorities and other bodies involved in the conformity assessment of medical 
devices. 
International Conference of Harmonisation (ICH) - Good Clinical Practice (GCP) E6(R2)39: 
An international ethical and scientific quality standard for designing, conducting, recording 
and reporting trials that involved the participation of human subjects.  
Regulatory authorities: Bodies having the power to regulate. Individual countries different 
regulatory requirements and enforcement abilities, for example, The United States (US) Food 
and Drug Administration (FDA) Guidelines for Monitoring of Clinical Investigations45, the 
European Union’s (EU) Clinical Trial Directive48 and the Australian Government’s National 
Statement on Ethical Conduct in Human Research49.  
Standard Operating 
Procedure (SOP) 
Detailed written instructions to achieve uniformity of a specific function. A written process of 
instructions necessary to carry out a policy or a way a task can be performed the same way 
each time39.  
 
Discussion  
A systematic approach to data quality monitoring is essential to ensure high data quality for confidence in data reuse and 
technological improvements for clinical research. The DQMF developed provides an easy-to-use guide for monitoring data 
quality of individual clinical research trials with reference to key international documents. Within the pharmaceutical/private 
industries 40 and information sciences literature, data quality audit tools and procedures appear to be well developed with 
many frameworks acknowledging the multiple dimensions of data quality 50-55. However, only a small body of clinical 
research has described the use of data quality frameworks 22, 40, 56-58, and even less have identified the appropriate methods to 
quantify the quality of data 30. Although many data quality dimensions and attributes have been determined within the clinical 
and health literature, the majority provide no usable definitions. Public sharing of such knowledge is crucial in developing a 
standardized approach that can be implemented across the clinical and broader research community to improve the rigor of 
clinical research. 
Many organizations collect and analyze data for their own benefit to meet SOPs and ensure quality assurance and control. In 
terms of quality assurance and quality control the SOP is one of the most generic, reusable and important documents within 
clinical research15. However, within academic research settings, published on-site audits that include quality assurance are 
less often reported. This may be due to unclear audit methods, lack of time and funding, audits perceived as unnecessary for 
unregulated studies and publishing SOPs is not seen as a ‘value added’ activity59-61. There is a general agreement among 
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leading clinical trial management groups that establishing reliable guidelines as a monitoring strategy would need to be 
determined on a risk-adapted basis for each trial36. It is recognized that different strategies need to be tailored for different 
types of clinical trials to determine adequate and appropriate monitoring41, 62. However, published methodology papers are 
warranted to promote routine auditing and monitoring within both academic and commercial research settings. Research 
grants seldom include funding for such programs63. The DQMF has gathered current published information on the conduct of 
clinical trial data management, albeit limited. The application of the framework is a vital implementation strategy to the 
overall improvement of the quality of clinical trial data and the follow-on-effect of results, conclusions and 
recommendations60.  Identifying all possible data discrepancies before they occur with all best intentions may not happen; 
therefore, a standardized framework, such as the one in this study, will provide useful guidance for the pragmatic 
implementation of continuous quality improvement.  
The interest in standardization within the clinical research community has grown in recent years and therefore, the DQMF 
considers data quality monitoring from a broad perspective. This generic framework brings together key concepts from the 
scientific literature, government documents, and policies to illustrate links between concepts and their effect on each other 
within and amongst layers. This differs from previously published frameworks, which have focused on specific concepts in 
isolation, not considering the inter- and intra-relationships. This singular approach has caused confusion within the clinical 
research space.  A survey conducted by the Clinical Trials Transformative Initiative (CTTI) found heterogeneity in data 
quality monitoring intensity, focus and methodology within and between academic/government, industry and clinical 
research organisations64. The utility of the DQMF is that it provides a single consolidated framework, which allows 
adaptations according to study context and data availability. This research will benefit the development of a long-term 
strategy and focus to fill the knowledge gap and reduce confusion around data quality monitoring in clinical research trials. 
Currently, as no standardized definitions apply across all clinical context. In correspondence with an increasing movement 
from paper-based forms to a digital and adaptive learning environment, it is necessary to improve the methods and approach 
to collection, storage and sharing of clinical research data. Electronic solutions are relatively new in clinical research and 
require major changes to existing procedures and professional training. Additionally, challenges arise in incorporating 
electronic data standards (CDISC and HL7) and the role they play in ensuring efficient and economic data sharing within 
clinical research65. The proposed DQMF provides guidance to clinical researchers on areas related to trial operations and 
ensuring high data quality throughout the entire research process. By utilizing this generic framework, it is anticipated to 
minimize the obstacles related to primary data quality and for the reuse of clinical research data. As the DQMF continues to 
evolve throughout the design-orientated approach, our knowledge and understanding of the challenges that arise from 
adapting to an electronic world will be addressed. This is vital to ensure the generic framework has future applicability.  
The holistic designed-orientated approach provided guidance to developing the DQMF by aiding the researchers to 
understand the clinical stakeholders. The framework aims to improve clinical research trial practices, which currently consists 
of complex, isolated and independent tools, procedures and frameworks. By providing an easily integrated knowledge 
development tool for clinical research practice the DQMF will support clinical research as a value-added function by 
providing oversight and guidance on the complex area of data quality monitoring. Additionally, providing clear definitions to 
concepts are key to its success. It should be highlighted that the proposed DQMF is developed from the published literature 
and draws on the personal experiences of the research team and the participants included in the face validation workshop. 
This may be considered a bias. A major limitation of the proposed DQMF is that it is yet to be applied in practice and 
implemented in a clinical research trial. The researchers stress the importance that application of the DQMF is required to test 
the framework within a broad spectrum of clinical research studies to identify facilitators and barriers, thereby ensuring best 
practice for data quality. According to the design-science research guidelines, further evaluation, contribution, rigor, and 
communication are needed to develop a convincing argument for the utility of this framework and its purpose for real world 
use. It is suggested that empirical research be conducted through the use of a reactive Delphi study66 to validate and allow 
experts to reach a consensus of opinion on the illustration, terms and what constitutes data quality monitoring in clinical 
research. The importance of industry wide definitions and methods are essential to enable strategic management and evaluate 
quality information. Without standardization, principle investigators of clinical research are left with inefficient data quality 
management.  
Conclusion 
A data quality monitoring framework (DQMF) has been developed for clinical research trials. The utility of this single 
consolidated framework is to reduce confusion around data quality monitoring whilst allowing for adaptations according to 
study context and data availability. The framework will guide new trials or identify procedures in existing trials to improve 
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data quality monitoring. The framework demonstrates how data quality monitoring develops over the life cycle of a clinical 
study and how knowledge management may guide new approaches to research. The DQMF must now be validated by 
applying the framework and terminology to various clinical research trials for real world use. This will be crucial to refine 
and evaluate the generic detailed framework.  Overall, the DQMF will aid in the development of a long-term strategy to 
increase efficacy for clinical research data quality monitoring.  
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